Skip to main content
Top
Published in: Rheumatology International 1/2004

01-01-2004 | Case Report

Aplastic anemia complicating systemic lupus erythematosus: successful management with cyclosporine

Authors: N. P. Singh, Anupam Prakash, Dheeraj Garg, Aman Makhija, Anjali Pathania, Nirupam Prakash, Samir Kubba, S. K. Agarwal

Published in: Rheumatology International | Issue 1/2004

Login to get access

Abstract

Anemia is common with connective tissue disorders, but pancytopenia is rare. We report a 22-year-old female who presented with menorrhagia, seizures, anemia, leukocytosis, thrombocytopenia, pericardial effusion, positive ANA, and evidence of vasculitis on CT head scan and was diagnosed with systemic lupus erythematosus (SLE). After 7 months of remission, she was readmitted with menorrhagia and pancytopenia. Investigations revealed aplastic anemia. She survived on transfusion support for 6 weeks, during which period she received methylprednisolone and cyclophosphamide pulses, and phenytoin was omitted but to no avail. Cyclosporine (300 mg/day) was started and the aplastic anemia responded. After 4 months of therapy, the cyclosporine was gradually tapered over the next 2 months. The patient has been on 10 mg/day of prednisolone for the last 6 months. Aplastic anemia is rare in SLE and the response to immunosuppressants is variable, but here is a success story.
Literature
1.
go back to reference Roffe C, Cahill MR, Samanta A, Bricknell S, Durrant ST (1991) Aplastic anaemia in systemic lupus erythematosus: a cellular immune mechanism? Br J Rheumatol 30:301–304 Roffe C, Cahill MR, Samanta A, Bricknell S, Durrant ST (1991) Aplastic anaemia in systemic lupus erythematosus: a cellular immune mechanism? Br J Rheumatol 30:301–304
2.
go back to reference Cline MJ, Golde DW (1978) Immune suppression of hematopoiesis. Am J Med 64:301–310PubMed Cline MJ, Golde DW (1978) Immune suppression of hematopoiesis. Am J Med 64:301–310PubMed
3.
go back to reference Marques JA, Rhim H, Distenfeld A (1995) Inhibition of hematopoiesis by a plasma factor in a case of aplastic anemia associated with systemic lupus erythematosus. P R Health Sci J 14:293–296PubMed Marques JA, Rhim H, Distenfeld A (1995) Inhibition of hematopoiesis by a plasma factor in a case of aplastic anemia associated with systemic lupus erythematosus. P R Health Sci J 14:293–296PubMed
4.
go back to reference Sumimoto S, Kawai M, Kasajima Y, Hamamoto T (1991) Aplastic anemia associated with systemic lupus erythematosus. Am J Hematol 38:329–331PubMed Sumimoto S, Kawai M, Kasajima Y, Hamamoto T (1991) Aplastic anemia associated with systemic lupus erythematosus. Am J Hematol 38:329–331PubMed
5.
go back to reference Winkler A, Jackson RW, Kay DS, Mitchell E, Carmignani S, Sharp GC (1988) High-dose intravenous cyclophosphamide treatment of systemic lupus erythematosus-associated aplastic anemia. Arthritis Rheum 31:693–694PubMed Winkler A, Jackson RW, Kay DS, Mitchell E, Carmignani S, Sharp GC (1988) High-dose intravenous cyclophosphamide treatment of systemic lupus erythematosus-associated aplastic anemia. Arthritis Rheum 31:693–694PubMed
6.
go back to reference Stricker RB, Shuman MA (1984) Aplastic anemia complicating systemic lupus erythematosus: response to androgens in two patients. Am J Hematol 17:193–201PubMed Stricker RB, Shuman MA (1984) Aplastic anemia complicating systemic lupus erythematosus: response to androgens in two patients. Am J Hematol 17:193–201PubMed
7.
go back to reference Morishita Y, Matsukawa Y, Kura Y et al (1997) Antithymocyte globulin for a patient with systemic lupus erythematosus complicated by severe pancytopenia. J Int Med Res 25:219–223PubMed Morishita Y, Matsukawa Y, Kura Y et al (1997) Antithymocyte globulin for a patient with systemic lupus erythematosus complicated by severe pancytopenia. J Int Med Res 25:219–223PubMed
8.
go back to reference Blackburn SC, Oliart AD, Garcia-Rodriguez LA, Perez-Gutthann S (1998) Antiepileptics and blood dyscrasias: a cohort study. Pharmacotherapy 18:1277–1283PubMed Blackburn SC, Oliart AD, Garcia-Rodriguez LA, Perez-Gutthann S (1998) Antiepileptics and blood dyscrasias: a cohort study. Pharmacotherapy 18:1277–1283PubMed
9.
go back to reference Huijgens PC, Thijs LG, den Ottolander GJ (1978) Pure red cell aplasia, toxic dermatitis and lymphadenopathy in a patient taking diphenylhydantoin. Acta Haematol 59:31–36PubMed Huijgens PC, Thijs LG, den Ottolander GJ (1978) Pure red cell aplasia, toxic dermatitis and lymphadenopathy in a patient taking diphenylhydantoin. Acta Haematol 59:31–36PubMed
10.
go back to reference Hinterberger-Fischer M, Hocker P, Lechner K, Seewann H, Hinterberger W (1989) Oral cyclosporin-A is effective treatment for untreated and also for previously immunosuppressed patients with severe bone marrow failure. Eur J Haematol 43:136–142 Hinterberger-Fischer M, Hocker P, Lechner K, Seewann H, Hinterberger W (1989) Oral cyclosporin-A is effective treatment for untreated and also for previously immunosuppressed patients with severe bone marrow failure. Eur J Haematol 43:136–142
Metadata
Title
Aplastic anemia complicating systemic lupus erythematosus: successful management with cyclosporine
Authors
N. P. Singh
Anupam Prakash
Dheeraj Garg
Aman Makhija
Anjali Pathania
Nirupam Prakash
Samir Kubba
S. K. Agarwal
Publication date
01-01-2004
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 1/2004
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-003-0318-z

Other articles of this Issue 1/2004

Rheumatology International 1/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.